Alvotech Enters Commercialization Agreement with Advanz Pharma for AVT10

Reported 2 days ago

Alvotech (NASDAQ:ALVO) has formed a commercialization agreement with Advanz Pharma to distribute AVT10, a biosimilar to Cimzia, in Europe. This deal is expected to strengthen Alvotech's position in the biosimilar market and could impact the market share of current treatments for chronic rheumatic diseases.

Source: YAHOO

View details

You may also interested in these wikis

Back to all Wikis